The use of luspatercept for thalassemia in adults

Research output: Contribution to journalArticlepeer-review


Luspatercept is an activin receptor ligand trap that has been shown to enhance late-stage erythropoiesis in animal models of b-thalassemia. A multicenter, international, phase 2 dosefinding study was initiated in adult patients with b-thalassemia, either non-transfusiondependent thalassemia (NTDT) or transfusion-dependent thalassemia (TDT). Positive results of the phase 2 study paved the way to a randomized phase 3 clinical trial (BELIEVE) to assess the efficacy and safety of luspatercept. The BELIEVE trial is a randomized, double-blind, placebo-controlled phase 3 trial. Three hundred thirty-six patients aged $18 years with TDT (regularly transfused, 6-20 red blood cell units within 24 weeks before randomization) were included in the trial. Patients received luspatercept or placebo subcutaneously every 21 days for$48weeks and best supportive care. Forty-eight of 224 patients (21.4%) in the luspatercept group achieved the primary end points (≥33% reduction in transfusion burden) compared with those in the placebo group (4.5%; P <.001). Moreover, more patients had a $33% reduction in transfusion burden during any rolling 12-week interval (70.5% vs 29.5%) or any 24-week interval (41.1% vs 2.7%) with luspatercept than with the placebo. Transfusion independence was achieved by 11% of patients in the luspatercept group. Transient adverse events were more frequent with luspatercept than with placebo, but were manageable. Luspatercept was approved by the US Food and Drug Administration in 2019 and by the European Medicines Agency in 2020. The luspatercept trial is registered onwww.clinicaltrials. gov at #NCT01749540 and the BELIEVE trial at #NCT02604433.

Original languageEnglish
Pages (from-to)326-333
Number of pages8
JournalBlood advances
Issue number1
Publication statusPublished - 2021

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'The use of luspatercept for thalassemia in adults'. Together they form a unique fingerprint.

Cite this